Ponpon S. Idjradinata
Department of Child Health, Faculty of Medicine, Universitas Padjadjaran-Hasan Sadikin Hospital

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

CINICO-EPIDEMIOLOGICAL PROFILE OF VITILIGO PATIENTS IN DR. HASAN SADIKIN GENERAL HOSPITAL BANDUNG Dwiyana, Reiva Farah; Marindani, Vani; Agustina, Rohana; Setiawan, Setiawan; Idjradinata, Ponpon S.; Sutedja, Endang
Majalah Kedokteran Bandung Vol 49, No 2 (2017)
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (452.63 KB) | DOI: 10.15395/mkb.v49n2.1056

Abstract

Vitiligo is the most common hypopigmentation disorder; however, until now there iss no comprehensive epidemiological-clinical study of vitiligo in Indonesia. A descriptive study  using a questionnaire among vitiligo patients in Dr. Hasan Sadikin General Hospital Bandung was conducted to determine the clinical findings, socio-demographic factors, coexisting autoimmune disorders, and severity of disease. All vitiligo patients were recruited during the period of February 2012 to April 2014 from the Dermatology Outpatient Clinic of Dr. Hasan Sadikin General Hospital Bandung, as well as from the Endocrinology and Rheumatology Clinic Department of Internal Medicine; Endocrinology and Allergy and Immunology Clinics Department of Child Health; and Department  of Nuclear Medicine the same hospital. We collected data on socio-demographic profiles, clinical profile, and severity of vitiligo based on Vitiligo European Task Force (VETF). Out of 242 patients, female patients made up the majority of the patients (66.12%). In addition, most patients  wereunder 20 years (33.47%) and experienced onset of vitiligo highest in the first decade of life (29.34%). About 19.42% had positive family history of vitiligo and only 6.2% had history of autoimmune diseases. The majority of patients (77.27%) had vulgaris type of vitiligo with  head-neck (35.36%) asthe most frequent initial site of onset. Based on VETF,  the skin affected was mostly below 10% of body surface area (82.23%), i.e. staging score of between 0?5 (57.44%), and spreading score of between >0?(+5) or 68.18%. It is concluded that vitiligo most commonly occurs in females with the highest onset of under 10-years old and strong relationship with genetic predisposition.T he affected area was relatively small, despite the high spreading score. [MKB. 2017;49(2):132?8]   Key words: Clinical profile, epidemiology, vitiligo  Profil Kliniko-Epidemiologi pada Pasien Vitiligo di RSUP Dr. Hasan Sadikin Bandung   Vitiligo merupakan kelainan hipopigmentasi tersering, tetapi hingga kini belum ada penelitian epidemiologi-klinik yang komprehensif di Indonesia. Penelitian deskriptif menggunakan kuesioner dilakukan pada pasien vitiligo di Rumah Sakit Dr. Hasan Sadikin Bandung untuk mengetahui gambaran klinis, faktor sosio-demografik, kelainan autoimun yang menyertai, dan keparahan penyakit. Seluruh pasien vitiligo dari periode Februari 2012 hingga April 2014 yang berkunjung ke poliklinik Kulit dan Kelamin Rumah Sakit Dr. Hasan Sadikin Bandung, serta poliklinik: Endokrinologi dan Rematologi, Ilmu Penyakit Dalam; Endokrinologi dan Alergi-imunologi, Ilmu Kesehatan Anak; serta Kedokteran Nuklir, diikutsertakan dalam penelitian. Data yang dihimpun mencakup keadaan sosiodemografi, klinik, dan keparahan vitiligo berdasar atas Vitiligo European Task Force (VETF). Dari 242 pasien, perempuan merupakan jenis kelamin terbanyak (66,12%), usia di bawah 20 tahun (33,47%), dan awitan vitiligo terjadi pada dekade pertama kehidupan (29,34%). Sekitar 19,42% memiliki riwayat vitiligo pada keluarga dan hanya 6,2% yang memiliki penyakit autoimun. Umumnya tipe vitiligo vulgaris (77,27%) dengan predileksi pertama pada kepala-leher (35,36%). Area kulit yang terkena berdasarkan VETF ialah di bawah 10% dari body surface area (82,23%), staging score 0?5 (57,44%), dan spreading score antara >0?(+5) atau 68,18%. Simpulan penelitian ini ialah vitiligo banyak mengenai perempuan, awitan tersering pada usia di bawah 10 tahun dengan predisposisi genetik yang tinggi, serta daerah yang terkena vitiligo relatif kecil meskipun spreading score-nya tinggi. [MKB. 2017;49(2):132?8]   Kata kunci: Epidemiologi, gambaran klinik, vitiligo
Risk Factors to Growth Retardation in Major Thalassemia Uda, Riva; Idjradinata, Ponpon S.; Djais, Julistio TB
Majalah Kedokteran Bandung Vol 43, No 1
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The increasing in the life span of patients with major thalassemia should be followed by increased quality of life. There are factors which can affect growth retardation in these patients. The aim of this study was to find out the risk factors for growth retardation in patients with major thalassemia. An analytical study with cross-sectional design was conducted at Pediatric Thalassemia Clinics of Dr.Hasan Sadikin Hospital, Bandung, in June to July 2006. The subjects of this study were patients with major thalassemia. Inclusion criteria’s were age under 14 years old, had no chronic diseases like tuberculosis, cerebral palsy with complete medical records. Risk factors were the timing of diagnosis, initial and dose of deferoxamine, volume of transfused blood, mean pretransfusion hemoglobin level, family income, and age. Antropometric measurement indices were used to assess the growth which expressed in Z score. Growth evaluated based on height/age (H/A) and growth retardation if H/A <-2 SD. Risk factors for growth retardation were analyzed separately using chi-square test and odds ratio (OR) with 95% confidence interval (CI). Then they were analyzed simultaneously with logistic regression method. Subjects consisted of 152 patients with major thalassemia. Seventy three thalassemia patients were stunted. Analysis showed that age (OR: 5.42, 95% CI:2.32–12.65, p <0.001), dosage of deferoxamine (OR: 4.0, 95% CI: 1.29–12.41, p: 0.016), and family income (OR: 2.32, 95% CI: 1.06–5.06, p: 0.036) were risks factors for growth retardation. Conclusion, risk factors for growth retardation in major thalassemia are age, dosage of deferoxamine, and family income. [MKB. 2011;43(1):21–5].Key words: Major thalassemia, risk factors, stuntedFaktor Risiko terhadap Gangguan Tumbuh pada Thalassemia MayorBertambahnya harapan hidup penderita thalassemia, seyogianya diikuti dengan kualitas hidup seperti anak normal. Terdapat berbagai faktor risiko yang mempengaruhi terjadinya gangguan tumbuh pada penderita thalassemia mayor. Tujuan penelitian ini untuk mengetahui berbagai faktor risiko terjadinya gangguan tumbuh pada penderita thalassemia mayor. Penelitian ini merupakan penelitian analitik dengan rancangan cross sectional di Poliklinik Anak thalassemia Dr. Hasan Sadikin, Bandung, pada bulan Juni–Juli 2006. Subjek penelitian ini adalah penderita thalassemia mayor. Kriteria inklusi adalah penderita berusia <14 tahun, tidak mempunyai penyakit kronik seperti tuberkulosis, palsi serebral, dan rekam medis yang lengkap. Faktor risiko adalah usia saat penegakan diagnosis, usia mulai menggunakan desferoksamin, dosis desferoksamin, volume darah yang telah diterima, kadar hemoglobin rata-rata sebelum transfusi, penghasilan keluarga, dan usia penderita. Dengan antropometri akan ditentukan pertumbuhan berdasarkan skor-Z. Pertumbuhan dinilai dari indeks tinggi badan/usia dan penderita yang mengalami gangguan tumbuh bila tinggi badan/usia <-2 SD. Faktor risiko gangguan tumbuh dianalisis menggunakan uji ki kuadrat dan rasio odds (RO) dengan interval kepercayaaan (IK) 95%, selanjutnya dilakukan analisis dengan metode regresi logistik. Subjek terdiri atas 152 penderita thalassemia mayor. Terdapat 73 penderita yang mengalami gangguan tumbuh. Hasil analisis menunjukkan usia penderita (RO 5,42; IK 95%: 2,32–12,65, p <0, 001), dosis desferoksamin (RO 4,0; IK95%:1,29–12,41, p: 0,016), dan penghasilan keluarga (RO 2,32; IK 95%:1,06–5,06, p: 0,036). merupakan faktor risiko terjadinya gangguan tumbuh. Simpulan, faktor risiko terjadinya gangguan tumbuh pada thalassemia mayor adalah usia, dosis desferoksamin, dan penghasilan keluarga. [MKB. 2011;43(1):21–5].Kata kunci: Faktor risiko, gangguan tumbuh, thalassemia mayor DOI: http://dx.doi.org/10.15395/mkb.v43n1.40